Researchers have identified a biomarker that can help predict a patient's prognosis and response to therapies for glioblastoma brain cancer subtypes.
A new study in the Journal of Experimental Medicine report Zika virus could be used to target and treat glioblastoma brain cancer. Researchers found a mouse adapted strain of Zika slowed tumor growth and extended life span in mice with glioblastoma.
Researchers have developed a new approach that uses microRNA in combination with chemotherapy to help treat glioblastoma brain cancer. In preclinical models, the approach increases survival of the deadly brain cancer five fold.
Recurrent gliomas could have genetic profiles which are different from those of the initial tumors that spawned them, a new study reports.
A new clinical trial will test whether an experimental vaccine can help patients' immune systems to stop the spread of deadly glioblastoma brain cancer.
A new study reports researchers have identified a mechanism that aids the growth of glioblastoma brain cancer. By blocking the mechanism, researchers were able to halt the progression of the tumors.
Researchers report our gender can determine longevity and response to treatment for glioblastoma brain cancer. The study reports male survival is determined by genes that control cell division, where as female survival is often determine by genes that regulate the ability of cancer cells to migrate to different brain areas.
A new Baylor study reveals the CD44s molecule gives glioblastoma brain cancer cells a survival advantage. Removing CD44s from cancer cells and treating with erlotinib helped to promote the death of cancer cells than by just treating the cancer with erlotinib alone, researchers said.
A new drug has been cleared for human trials in patients with anaplastic astrocytoma and glioblastoma brain cancers. The drug, PAC-1, is reported to spur cancer cells to self destruct and has proven to be effective in animal models of brain cancers.